Osteoporosis and cancer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Antiresorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Nonpharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

Original languageEnglish (US)
Pages (from-to)163-170
Number of pages8
JournalCurrent Osteoporosis Reports
Volume11
Issue number3
DOIs
StatePublished - Sep 2013

Fingerprint

Osteoporosis
Bone
Neoplasms
Bone and Bones
Cells
Bone Fractures
Skeleton
Prostatic Neoplasms
Guidelines
Breast Neoplasms
Survival
Therapeutics

Keywords

  • Aromatase inhibitor
  • Bisphosphonate
  • Bone
  • Breast
  • Calcium
  • Cancer
  • Denosumab
  • Exercise
  • Myeloma
  • Osteoporosis
  • Prostate
  • Vitamin D

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Osteoporosis and cancer. / Drake, Matthew M.

In: Current Osteoporosis Reports, Vol. 11, No. 3, 09.2013, p. 163-170.

Research output: Contribution to journalArticle

Drake, Matthew M. / Osteoporosis and cancer. In: Current Osteoporosis Reports. 2013 ; Vol. 11, No. 3. pp. 163-170.
@article{b7d4b780b4d24143808a689ddd34c316,
title = "Osteoporosis and cancer",
abstract = "Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Antiresorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Nonpharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.",
keywords = "Aromatase inhibitor, Bisphosphonate, Bone, Breast, Calcium, Cancer, Denosumab, Exercise, Myeloma, Osteoporosis, Prostate, Vitamin D",
author = "Drake, {Matthew M}",
year = "2013",
month = "9",
doi = "10.1007/s11914-013-0154-3",
language = "English (US)",
volume = "11",
pages = "163--170",
journal = "PLoS Medicine",
issn = "1549-1277",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Osteoporosis and cancer

AU - Drake, Matthew M

PY - 2013/9

Y1 - 2013/9

N2 - Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Antiresorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Nonpharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

AB - Cancer is a major risk factor for bone loss and fractures. This is due both to direct effects of cancer cells on the skeleton and to deleterious effects of cancer-specific therapies on bone cells. Marked improvements in survival for many cancers mean that strategies to limit bone loss and reduce fracture risk must be incorporated into the care plans for nearly all patients with cancer. The vast majority of effort thus far has focused on bone loss in patients with breast and prostate cancers, with comparatively few studies in other malignancies. Antiresorptive therapies have proven nearly universally effective for limiting bone loss in cancer patients, although few studies have been powered sufficiently to include fractures as primary endpoints, and patients are frequently neither identified nor treated according to published guidelines. Nonpharmacologic approaches to limit falls, particularly in elderly patients, are also likely important adjunctive measures for most cancer patients.

KW - Aromatase inhibitor

KW - Bisphosphonate

KW - Bone

KW - Breast

KW - Calcium

KW - Cancer

KW - Denosumab

KW - Exercise

KW - Myeloma

KW - Osteoporosis

KW - Prostate

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84885297795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885297795&partnerID=8YFLogxK

U2 - 10.1007/s11914-013-0154-3

DO - 10.1007/s11914-013-0154-3

M3 - Article

C2 - 23877475

AN - SCOPUS:84885297795

VL - 11

SP - 163

EP - 170

JO - PLoS Medicine

JF - PLoS Medicine

SN - 1549-1277

IS - 3

ER -